Physician profile
Ashley Milner
NPI 1831780105
$405.33
in general payments reported to CMS, 2019-2025
11 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $21.40 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.81 | 2025 | Verquvo |
| Bridgebio Pharma, INC. | $63.51 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $56.61 | 2025 | |
| Lilly USA, LLC | $41.97 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $32.50 | 2025 | |
| Esperion Therapeutics, INC. | $24.48 | 2025 | Nexletol |
| Edwards Lifesciences Corporation | $23.64 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $21.40 | 2024 | Farxiga |
| Abiomed | $20.29 | 2025 | |
| Vivaquant INC, Dba Rhythm Express | $17.59 | 2025 | Rhythm Express |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.53 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Milner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.